ESTABLISHMENT AND CHARACTERIZATION OF CELL LINE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA

DOI
  • TAKAI Yoko
    Department of Innovative Seeds Evaluation, National Cancer Center Research Institute
  • OYAMA Rieko
    Department of Innovative Seeds Evaluation, National Cancer Center Research Institute
  • KITO Fusako
    Department of Innovative Seeds Evaluation, National Cancer Center Research Institute
  • SAKUMOTO Marimu
    Department of Innovative Seeds Evaluation, National Cancer Center Research Institute
  • SHIOZAWA Kumiko
    Division of Rare Cancer Research, National Cancer Center Research Institute
  • QIAO Zhiwei
    Division of Rare Cancer Research, National Cancer Center Research Institute
  • NAKAJIMA Kosei
    Division of Rare Cancer Research, National Cancer Center Research Institute
  • TAKAHASHI Mami
    Central Animal Division, National Cancer Center Research Institute
  • YOSHIDA Akihiko
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital
  • SETSU Nokitaka
    Division of Musculoskeletal Oncology, National Cancer Center Hospital
  • KOBAYASHI Eisuke
    Division of Musculoskeletal Oncology, National Cancer Center Hospital
  • KAWAI Akira
    Division of Musculoskeletal Oncology, National Cancer Center Hospital
  • KONDO Tadashi
    Department of Innovative Seeds Evaluation, National Cancer Center Research Institute Central Animal Division, National Cancer Center Research Institute

この論文をさがす

抄録

<p>Background: Undifferentiated pleomorphic sarcoma (UPS) is an aggressive mesenchymal malignancy. Although patient-derived cell lines are invaluable tools for preclinical studies, there are only a few UPS cell lines available in public cell banks. In the present study, we established a cell line from the primary tumor tissue of a UPS patient. Methods: Primary UPS tumor tissues were sampled to establish cell lines. Morphological and proteomic analyses were performed and sensitivity to anti-cancer drugs was evaluated. Results: We established a novel UPS cell line, namely NCC-UPS1-C1 cells, and maintained the cells for over 100 passages. The characters of cells as morphology, growth rate, colony formation capacity, and immune-histochemical traits were confirmed. Mass spectrometric protein expression profiling revealed that the proteome of the original tumor tissue differed from that of the cell line. Sensitivity to 164 anti-cancer drugs was screened for their growth inhibitory effects. Conclusions: Patient-derived cell line in this study may be useful for understanding the molecular background of drug resistance in UPS. Furthermore, the use of the patient-derived cancer model will facilitate our understanding of molecular mechanisms underlying poor prognosis, and will contribute to novel therapeutic strategies.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ